Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

Abstract

Purpose

To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients.

Setting

Retrospective chart analysis.

Method

A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye disease and were treated with lifitegrast 5% ophthalmic solution for 6 months. Collected symptom data included improvement of eye dryness, tearing, eye pain, fluctuation in vision, foreign body sensation, itching, grittiness, burning and contact lens intolerance if applicable. Collected clinical signs included changes in superficial punctate keratitis, corneal fluorescein staining, conjunctival hyperemia and presence of tear debris.

Results

Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. Improvements were also observed in corneal and conjunctival staining and tear debris for most of the patients reviewed.

Conclusion

Treatment with lifitegrast twice a day for 6 months improved both signs and symptoms of chronic dry eye.

Keywords:

• lifitegrast
• integrin antagonist
• dry eye disease
• DED
• eye dryness
• inflammation
• ocular surface disease

Disclosure

Dr Eric Donnenfeld has been a consultant for Shire, the manufacturer of Xiidra (lifitegrast ophthalmic solution 5%). Dr Richard Najac reports personal fees from Shire outside the submitted work. Dr Eric Donnenfeld reports personal fees from Shire during the conduct of the study and personal fees from Allergan and Bausch & Lomb outside the submitted work. The authors report no other conflicts of interest in this work.